Suzhou Labyrinth Biotech Co., Ltd. is pleased to announce its participation in the World Conference on Lung Cancer (WCLC) 2025, held in Barcelona, Spain from September 6 to 9, where it will present its latest research findings in the form of an E-Poster.
Learn More >
On August 12, 2023, the International Exchange and Cooperation Center of the National Health Commission, in collaboration with VB100, hosted the "2023 Medical Device Innovation and International Cooperation Summit." At the summit, Suzhou Labyrinth Biotech was awarded the "VB-Find Award: 2023 Most Innovative Medical Device Product (Solution)" for its original rare cell sorting and enrichment technology.
Learn More >_GuweMAnr.jpg)
This symposium features Prof. Majid E. Warkiani, a globally renowned microfluidics expert and Chief Technology Officer of Labyrinth, as the keynote speaker. He will highlight the revolutionary applications of "Label-Free Viable Rare Tumor Cell Microfluidic Technology" in rare cell isolation, precision oncology, stem cell therapy, and in vitro fertilization.
Learn More >
Recently, Professor Yu Hanry, a distinguished tenured professor at the National University of Singapore (NUS) and an internationally acclaimed expert in biomedical imaging and precision medicine, visited Suzhou Labyrinth Biotech Co.,Ltd.
Learn More >
July 18, 2025 – Labyrinth, in collaboration with Peking Union Medical College Hospital, has been granted a Chinese invention patent (No. ZL2025 1 0480497.X) for its "Human PDAC Ascites-Derived Tumor Cell Line and Applications".
Learn More >![[Invitation] International Microfluidics Symposium | Labyrinth & NUS Jointly Explore a New Era in Label-Free Rare Tumor Cell Capture](/UserFiles/Article/News/Seminar NUS-Labyrinth new3(2)(1)_INZSl2eH.jpg)
Microfluidics technology, serving as a critical bridge between conventional laboratory techniques and cutting-edge biological research, is increasingly demonstrating its immense potential in precision medicine applications. To foster academic exchange and technological advancement in this field, Suzhou Labyrinth Biotech Co., Ltd. and the National University of Singapore (NUS) Yong Loo Lin School of Medicine jointly organized the international symposium on 'Label-Free Microfluidic System for Rare Circulating Tumor Cell Capture' on August 5, 2025.
Learn More >
Our CTC detection technology can accurately capture circulating tumor cells from the blood—even when the number of cancer cells is extremely low—providing critical data to inform your treatment plan," our technical expert explained to Ms. W during the phone consultation. After addressing her concerns, we immediately prioritized her case through our green channel fast-track service, ensuring her blood sample would be processed ahead of schedule. We also guaranteed the fastest possible turnaround time for her test results.
Learn More >
Recently, in collaboration with Peking Union Medical College Hospital (PUMCH) - specifically Professor Rui Chen's team from the Clinical Pharmacology Research Center and Professor Jiaxin Yang's team from the Gynecological Oncology Clinical Research Center - we published a landmark study titled "Human malignant ovarian germ cell tumor cell lines derived from peritoneal cytology retrieving from circulating tumor cell system" in the international journal Cancer Treatment and Research Communications.
Learn More >
A fun science animation that helps you better understand what makes Labyrinth technology unique
Learn More >
